OBSV News and Press, ObsEva SA From 04/25/22

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 25 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – April 7 , 202 2 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing nov...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – March 31 , 202 2 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializin...

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively, and these reductions increased up to 6 months- -A similar pattern of improve...

ObsEva press release (NASDAQ:OBSV): FY GAAP EPS of -$0.78 misses by $0.05. Revenue of $20.11M in-line. Cash and cash equivalents of $54.7 million at December 31, 2021 compared to $31.2 million at December 31, 2020. Shares +2.48% PM For further de...

-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Entered strategic licen...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Meritor (NYSE:MTOR) +43% Cummins acquires Meritor with eyes on electric power applications. Digital World Acquisition (NASDAQ:DWAC) +17% Trump's TRUTH Social platform hits Apple's App Store. Ocugen (NASDAQ:OCGN) +16% after FDA lifted hold on study for COVID-19 va...

ObsEva (NASDAQ:OBSV) signed a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in markets outside of the U.S., Canada and Asia. OBSV is entitled to receive royalties of a mid-thirties percentage on commercial sales, which includes the co...

- Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an oral GnRH ant...